A. Salapatek

Double‐blind, placebo‐controlled, dose‐ranging study of new recombinant hypoallergenic Bet v 1 in an environmental exposure chamber

Wally Meyer, Annemie Narkus, A. Salapatek et al. · Allergy · 2013 · 70 citations

Validation of Peptide Immunotherapy as a New Approach in the Treatment of Allergic Rhinoconjunctivitis: The Clinical Benefits of Treatment with Amb a 1 Derived T cell Epitopes

Rod Hafner, A. Salapatek, D. Patel et al. · Journal of Allergy and Clinical Immunology · 2012 · 28 citations

Provocation of nonallergic rhinitis subjects in response to simulated weather conditions using an environmental exposure chamber model

Jonathan A. Bernstein, A. Salapatek, Joanne S. Lee et al. · Allergy and Asthma Proceedings · 2012 · 26 citations

Asthma, Nonallergic Rhinitis, Environmental Allergy +18

Ca²⁺ influx and cAMP elevation overcame botulinum toxin A but not tetanus toxin inhibition of insulin exocytosis

Xiaohang Huang, Youhou Kang, Ewa A. Pasyk et al. · American Journal of Physiology-Cell Physiology · 2001 · 23 citations

Persistent Treatment Effect Achieved At One Year After Four Doses Of Der p Derived Synthetic Peptide Immuno-Regulatory Epitopes In An Exposure Chamber Model Of House Dust Mite Allergy

Rod Hafner, Peter Couroux, Kristen Armstrong et al. · Journal of Allergy and Clinical Immunology · 2014 · 19 citations · Full text

Asthma, Environmental Allergy, Allergy +10